Jefferies Boosts Price Target for Liquidia (NASDAQ: LQDA) on Strong YUTREPIA Performance

Font: Financial Modeling Prep  • May 11, 2026

• Jefferies analyst Amy Li raised the price target for Liquidia to $60.00, signaling increased confidence in the biopharmaceutical company's future.
• The company reported robust Q1 2026 revenues of approximately $133.00 million and a significant turnaround to $0.52 per share in earnings, largely driven by its successful drug, YUTREPIA.
• Liquidia achieved its third consecutive quarter of profitability with a net income of about $53.00 million, leading to a 25.60% stock increase and a new 52-week high of $53.93.

Jefferies analyst Amy Li has raised the price target for Liquidia (NASDAQ: LQDA) to $60.00 from $57.00. This positive outlook for the biopharmaceutical stock reflects increased confidence in the company's future performance. Liquidia, a biopharmaceutical company focused on developing treatments for pulmonary diseases, saw its new price target set when the stock was trading at $53.13.

This positive outlook follows Liquidia's strong first-quarter 2026 results. The company's success in the biotech sector is largely driven by its innovative drug, YUTREPIA, which treats serious lung conditions. Since its launch, YUTREPIA has become a major growth driver in its market, showing significant adoption by both patients and doctors, underscoring its impact on pulmonary disease treatment.

Financially, Liquidia reported robust revenues of approximately $133.00 million for the quarter, a massive increase from about $3.00 million in the same period last year. As highlighted by Zacks, the company also posted strong quarterly earnings of $0.52 per share. This represents a notable turnaround from the loss of $0.45 per share reported a year ago, showcasing significant financial performance improvement.

The market's response to YUTREPIA is strong, indicating high patient and physician confidence. As of April 30, the company received around 4,500 unique patient prescriptions and started treatment for about 3,750 patients. Physician confidence is also growing, with roughly 980 doctors prescribing the drug and the number of heavy prescribers increasing by 25% since February, highlighting successful drug market penetration.

The company has now achieved its third straight quarter of profitability, with a net income of about $53.00 million. This strong performance has significantly boosted its stock, which saw a daily increase of 25.60% to hit a new 52-week high of $53.93. The company's market capitalization, or total value, is now approximately $4.68 billion, reflecting growing investor confidence in this biotech stock.